Skip to main content

Table 3 Baseline characteristics of AIS patients according to quartiles of admission serum TBA

From: Increased admission serum total bile acids can be associated with decreased 3-month mortality in patients with acute ischemic stroke

Variables

Total

(777)

Q 1

≤3.0 (197)

Q 2

3.0-5.7 (195)

Q 3

5.7-9.5 (191)

Q 4

>9.5 (194)

P-value

Age (years), median (IQR)

71 (62-78)

69 (61-77)

70 (62-78)

71 (62-78)

72 (63-79)

0.623

Sex (male), n (%)

420 (54.1%)

104 (52.8%)

100 (51.3%)

109 (57.1%)

107 (55.2%)

0.677

Time from onset to admission (hours), median (IQR)

11 (3-25)

9 (3-22)

13 (4-28)

12 (4-27)

8 (3-27)

0.156

NIHSS score on admission, median (IQR)

4 (3-8)

5 (3-8)

5 (3-8)

4 (3-6)

4 (3-8)

0.389

Thrombolytic therapy, n (%)

31 (4.0%)

11 (5.6%)

2 (1.0%)

7 (3.7%)

11 (5.7%)

0.064

SBP (mmHg), median (IQR)

150 (140-170)

155 (140-170)

150 (140-163)

150 (140-170)

150 (130-170)

0.861

DBP (mmHg), median (IQR)

89 (80-95)

87 (80-95)

90 (80-95)

90 (80-98)

89 (80-95)

0.929

Previous stroke, n (%)

185 (23.8%)

42 (21.3%)

50 (25.6%)

45 (23.6%)

48 (24.7%)

0.769

Hypertension, n (%)

547 (70.4%)

139 (70.6%)

143 (73.3%)

129 (67.5%)

136 (70.1%)

0.667

Diabetes, n (%)

179 (23.0%)

43 (21.8%)

49 (25.1%)

43 (22.5%)

44 (22.7%)

0.876

Coronary heart disease, n (%)

37 (4.8%)

9 (4.6%)

13 (6.7%)

8 (4.2%)

7 (3.6%)

0.516

Atrial fibrillation, n (%)

113 (14.5%)

28 (14.2%)

27 (13.8%)

18 (9.4%)

40 (20.6%)

0.020

Heart failure, n (%)

23 (3.0%)

4 (2.0%)

5 (2.6%)

5 (2.6%)

9 (4.6%)

0.443

Smoking history, n (%)

210 (27.0%)

51 (25.9%)

47 (24.1%)

58 (30.4%)

54 (27.8%)

0.548

Drinking history, n (%)

166 (21.4%)

42 (21.3%)

39 (20.0%)

48 (25.1%)

37 (19.1%)

0.487

WBC (×109/L), median (IQR)

6.4 (5.3-8.1)

6.8 (5.6-8.5)

6.3 (5.0-7.8)

6.7 (5.4-8.3)

6.3 (5.1-7.9)

0.032

Platelet (×109/L), median (IQR)

178 (143-217)

185 (150-225)

173 (139-217)

182 (151-216)

170 (138-205)

0.072

Hemoglobin concentration (g/L), median (IQR)

135 (123-146)

134 (121-145)

134 (123-146)

136 (127-146)

134 (124-145)

0.373

ALB (g/L), mean (SD)

38.5 (3.3)

38.6 (3.3)

38.8 (3.3)

38.6 (3.4)

38.3 (3.2)

0.666

ALT (U/L), median (IQR)

19 (13-26)

19 (13-25)

19 (13-27)

18 (14-25)

19 (14-28)

0.941

AST (U/L), median (IQR)

23 (19-28)

23 (19-28)

23 (19-28)

22 (19-27)

23 (19-27)

0.546

Blood glucose (mmol/L), median (IQR)

5.5 (4.9-6.7)

5.7 (5.0-6.9)

5.6 (4.8-7.0)

5.4 (4.9-6.3)

5.5 (5.0-6.7)

0.537

TG (mmol/L), median (IQR)

1.3 (0.9-1.8)

1.2 (0.9-1.7)

1.3 (0.9-1.9)

1.4 (1.0-1.9)

1.3 (0.9-1.9)

0.173

TC (mmol/L), median (IQR)

4.6 (3.9-5.3)

4.7 (3.9-5.2)

4.6 (3.9-5.3)

4.5 (3.9-5.3)

4.5 (3.9-5.2)

0.976

LDL-C (mmol/L), mean (SD)

2.7 (0.9)

2.7 (0.8)

2.8 (1.0)

2.7 (0.9)

2.6 (0.9)

0.577

HDL-C (mmol/L), median (IQR)

1.3 (1.0-1.5)

1.3 (1.0-1.5)

1.2 (1.1-1.5)

1.2 (1.0-1.5)

1.3 (1.0-1.6)

0.510

SCr (µmoI/L), median (IQR)

72 (60-84)

70 (59-84)

72 (62-83)

72 (61-82)

71 (57-85)

0.900

Uric acid (µmoI/L), median (IQR)

304 (234-381)

287 (223-379)

303 (238-387)

308 (237-380)

310 (238-381)

0.655

  1. Except for the history of atrial fibrillation (AF) and the admission white blood cell (WBC) count, there were no significant differences in other baseline demographic, clinical and laboratory parameters among the four groups